Anteris Technologies and v2vmedtech, a structural heart company developing a next-generation transcatheter edge-to-edge repair (TEER) system for mitral and tricuspid valve regurgitation, today announced they have reached concept lock on the first phase of the system.
The VClip system is designed to overcome limitations that can prevent optimal procedural outcomes or limit eligibility of TEER for mitral and tricuspid valve disease.
Vinayak Bapat, chief medical officer for v2vmedtech, commented: “Today’s concept lock provides us important proof of concept data. Working closely with engineers and leading interventional cardiologists has allowed us to proceed rapidly as we drive innovation in the TEER space.”
David St Denis, chief executive officer of v2vmedtech and chief operating officer of Anteris Technologies, commented: “Achieving this milestone is an important step as we advance VClip toward a first-in-human study. Applying the same physician led collaborative design model as we successfully deployed in the development of DurAVR has allowed us to make significant progress in a rapid manner.”
